Federal contract award
75N93020F00003
STUDY P213
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN81 — AIDS RESEARCH - BASIC RESEARCH |
| Parent award / vehicle | 75N93020D00007 |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $3.7M |
| Current contract value | $3.7M |
| Potential contract value / ceiling | $3.7M |
| Start date | Sep 23, 2020 |
| Current end date | Oct 31, 2025 |
| Potential end date | Oct 31, 2025 |
| Latest award activity | Aug 21, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 21, 2025 | P00007 | $-15.3K | SIMIAN VACCINE EVALUATION UNITS (SVEUS) |
| Jun 26, 2025 | P00006 | $-21.9K | STUDY P213, "EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 SOSIP ENVELOPE PROTEIN VACCINE DELIVERED WITH OR WITHOUT RECOMBINANT VIRAL VECTOR VACCINES" |
| Mar 10, 2025 | P00005 | $0 | STUDY P213, "EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 SOSIP ENVELOPE PROTEIN VACCINE DELIVERED WITH OR WITHOUT RECOMBINANT VIRAL VECTOR VACCINES" |
| Dec 18, 2023 | P00004 | $676.8K | STUDY P213, "EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 SOSIP ENVELOPE PROTEIN VACCINE DELIVERED WITH OR WITHOUT RECOMBINANT VIRAL VECTOR VACCINES" |
| Apr 10, 2023 | P00003 | $0 | STUDY P213, "EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 SOSIP ENVELOPE PROTEIN VACCINE DELIVERED WITH OR WITHOUT RECOMBINANT VIRAL VECTOR VACCINES" |
| Jan 23, 2023 | P00002 | $1.1M | STUDY P213, "EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 SOSIP ENVELOPE PROTEIN VACCINE DELIVERED WITH OR WITHOUT RECOMBINANT VIRAL VECTOR VACCINES" |
| Feb 1, 2022 | P00001 | $0 | STUDY P213, "EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 SOSIP ENVELOPE PROTEIN VACCINE DELIVERED WITH OR WITHOUT RECOMBINANT VIRAL VECTOR VACCINES" |
| Sep 21, 2020 | 0 | $1.9M | STUDY P213 |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.